RAS/MAPK pathway mutations show association with adverse survival outcomes in myelofibrosis

Abstract data presented during the virtual 2020 European Hematology Association Annual Congress demonstrated an association between inferior survival outcomes and adverse phenotypic features among patients with RAS/MAPK pathway mutation (RASMT)–positive (ie, NRAS, KRAS or CBL) myelofibrosis (MF). Additionally, patients with mutations in the RAS/MAPK pathway had an inferior response to JAK inhibitors. The median survival for patients with RASMT-positive MF treated with a JAK2 inhibitor was 30 months vs 91 months for patients without RASMT (HR, 4.6; 95% CI, 2.0-10.6; P =.0001).